Kristina Jankovic, Medical Oncology Resident at the University Clinical Center Niš, shared an article by Charles E. Geyer on X:
“Data from KATHERINE trial confirms T-DM1 improves OS & sustains IDFS in HER2+ early Breast Cancer with residual disease after neoadjuvant therapy.
- 7-year IDFS: 80.8% (T-DM1)67.1% (trastuzumab)
- 7-year OS: 89.1% (T-DM1)84.4% (trastuzumab)
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Authors: Charles E. Geyer, et al.
